Impact of maternal first trimester valproate treatment regimen on the risk of birth defects

Researchers from TIS Berlin (Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy,
Charité РUniversitätsmedizin Berlin) have published an analysis of 484 first trimester valproate exposed pregnancies which investigates the effects of valproate dose and first trimester treatment discontinuation on the risks of spontaneous abortion and major birth defects. More information is available here.